<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR128">
 <label>128.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Matthay</surname>
    <given-names>MA</given-names>
   </name>
   <name>
    <surname>Calfee</surname>
    <given-names>CS</given-names>
   </name>
   <name>
    <surname>Zhou</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Thompson</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Wilson</surname>
    <given-names>JG</given-names>
   </name>
   <name>
    <surname>Levitt</surname>
    <given-names>JE</given-names>
   </name>
   <name>
    <surname>Rogers</surname>
    <given-names>AJ</given-names>
   </name>
   <name>
    <surname>Gotts</surname>
    <given-names>JE</given-names>
   </name>
   <name>
    <surname>Wiener-Kronish</surname>
    <given-names>JP</given-names>
   </name>
   <name>
    <surname>Bajwa</surname>
    <given-names>EK</given-names>
   </name>
   <name>
    <surname>Donahoe</surname>
    <given-names>MP</given-names>
   </name>
   <name>
    <surname>McVerry</surname>
    <given-names>BJ</given-names>
   </name>
   <name>
    <surname>Ortiz</surname>
    <given-names>LA</given-names>
   </name>
   <name>
    <surname>Exline</surname>
    <given-names>ME</given-names>
   </name>
   <name>
    <surname>Christman</surname>
    <given-names>JW</given-names>
   </name>
   <name>
    <surname>Abbot</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Delucchi</surname>
    <given-names>KL</given-names>
   </name>
   <name>
    <surname>Caballero</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>McMillan</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>McKenna</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>KD</given-names>
   </name>
  </person-group>
  <article-title>Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial</article-title>
  <source>Lancet Respiratory Medicine</source>
  <year>2019</year>
  <volume>7</volume>
  <issue>2</issue>
  <fpage>154</fpage>
  <lpage>162</lpage>
  <?supplied-pmid 30455077?>
  <pub-id pub-id-type="pmid">30455077</pub-id>
 </element-citation>
</ref>
